Healthcare tech company Omnicell (NASDAQ: OMCL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 14.9% year on year to $309.9 million. Guidance for next quarter’s revenue was better than expected at $310 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.55 per share was 66% above analysts’ consensus estimates.
Is now the time to buy OMCL? Find out in our full research report (it’s free for active Edge members).
Omnicell (OMCL) Q1 CY2026 Highlights:
- Revenue: $309.9 million vs analyst estimates of $304.5 million (14.9% year-on-year growth, 1.8% beat)
- Adjusted EPS: $0.55 vs analyst estimates of $0.33 (66% beat)
- Adjusted EBITDA: $44.65 million vs analyst estimates of $31.37 million (14.4% margin, 42.3% beat)
- The company reconfirmed its revenue guidance for the full year of $1.24 billion at the midpoint
- Management raised its full-year Adjusted EPS guidance to $1.90 at the midpoint, a 8.6% increase
- EBITDA guidance for the full year is $160.5 million at the midpoint, above analyst estimates of $153.3 million
- Operating Margin: 5.4%, up from -4.3% in the same quarter last year
- Market Capitalization: $2.07 billion
StockStory’s Take
Omnicell’s first quarter was marked by strong execution and operational improvements, leading to results that exceeded Wall Street’s expectations. Management attributed this momentum to rising adoption of its connected devices portfolio, disciplined cost control, and a healthy backlog of orders entering the year. CEO Randall Lipps emphasized that customer demand is increasingly driven by the need for enterprise-wide medication management solutions, particularly as health systems face staffing constraints and push for greater standardization. Lipps highlighted recent wins with large healthcare organizations, such as the U.S. Department of Veterans Affairs, as evidence of Omnicell’s position as a trusted partner for end-to-end medication workflows.
Looking forward, Omnicell’s raised profit guidance is underpinned by ongoing expansion of its recurring revenue streams and the rollout of Titan XT, its next-generation dispensing platform. Management expects these initiatives to drive continued margin expansion, with CFO Baird Radford noting that increased revenue linearity and improved customer scheduling should provide greater financial predictability throughout the year. While management remains mindful of potential headwinds from tariffs and evolving capital spending behaviors among health systems, Lipps stated that "the shift toward integrated, autonomous medication management directly supports our long-term growth ambitions and deeper partnerships with health systems."
Key Insights from Management’s Remarks
Management pointed to several factors driving Omnicell’s first quarter results, including product portfolio strength, growing recurring revenue, and early customer feedback on new platform launches.
- Connected devices momentum: Growth in the Connected Devices segment, particularly in North America and international markets, played a central role in driving first quarter revenue. Management noted this was supported by customer demand for scalable and reliable medication management solutions amid ongoing labor and cost pressures in healthcare settings.
- Recurring revenue expansion: The Specialty and Consumables business saw strong engagement, contributing to increased recurring revenue. Management emphasized that expanding reoccurring revenue streams is crucial for financial visibility and supports further investment in engineering and advanced analytics.
- OmniSphere and Titan XT launch: The formal introduction of Titan XT, Omnicell’s next-generation automated dispensing system, and the OmniSphere cloud platform generated positive customer feedback. Early adopters highlighted enhanced workflow efficiencies and migration flexibility—features designed to address labor shortages and operational variability in hospitals.
- Margin improvement through cost discipline: Improved non-GAAP gross margin was attributed to favorable product and customer mix in connected devices, as well as lapping prior-year software upgrade costs. Management cautioned that margin fluctuation should be expected in future quarters due to mix and timing factors.
- Competitive wins and pipeline growth: Omnicell continues to gain market share through competitive conversions, supported by a robust pipeline and increased customer interest in enterprise-wide solutions. Management believes the company is well positioned to benefit from competitors’ product issues and broader healthcare system reassessment of incumbent platforms.
Drivers of Future Performance
Omnicell’s outlook centers on scaling enterprise platform adoption, expanding recurring revenue, and managing margin headwinds from tariffs and investment in new technologies.
- Titan XT adoption and rollout: Management anticipates the phased rollout of Titan XT hardware in the second half of the year and OmniSphere software features in early next year will enable customers to migrate at their own pace, supporting long-term replacement cycles. This is expected to drive demand from large health systems seeking greater standardization and workflow automation.
- Recurring revenue and service growth: The company’s focus on expanding recurring revenue—especially through Specialty Pharmacy Services and consumables—should provide greater financial predictability and support investment in AI-driven analytics. Management projects annual recurring revenue to grow as more health systems adopt Omnicell’s enterprise offerings.
- Margin pressures and cost controls: While tariffs and ongoing investments in product development may pressure margins, management expects disciplined cost control and operating leverage to offset these headwinds. The updated outlook assumes roughly $12 million in tariff-related costs for the year, with continued focus on balancing growth and profitability.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the pace and breadth of Titan XT and OmniSphere deployments as initial customers migrate to the new platform, (2) sustained growth in recurring revenue streams from Specialty Pharmacy Services and consumables, and (3) the company’s ability to maintain margin discipline despite tariff-related costs and continued investment in product innovation. Execution on competitive conversions and pipeline expansion will also be important signposts for Omnicell’s progress.
Omnicell currently trades at $45.16, up from $37.63 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
